Fate Therapeutics
FATE
139 hedge funds and large institutions have $88.9M invested in Fate Therapeutics in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 45 increasing their positions, 40 reducing their positions, and 21 closing their positions.
560% more call options, than puts
Call options by funds: $264K | Put options by funds: $40K
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
17% more capital invested
Capital invested by funds: $76.3M → $88.9M (+$12.6M)
13% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 40
5% more funds holding
Funds holding: 132 → 139 (+7)
14.77% less ownership
Funds ownership: 84.28% → 69.51% (-15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$656K |
| 2 |
Jane Street
New York
|
+$467K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$304K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$298K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$296K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$7.98M |
| 2 |
JP Morgan Chase
New York
|
-$3.88M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.79M |
| 4 |
O
OrbiMed
New York
|
-$1.33M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.15M |
FATE Hedge Fund Activity: Q2 2025 in Review
139 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2025, worth a combined $88.9M — up 17% from $76.3M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new FATE positions and 21 closed out — a net gain of 7 holders — while 45 added to existing stakes and 40 trimmed.
The largest buyer was Millennium Management, adding an estimated $656K. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $7.98M.
- 139 institutional investors held Fate Therapeutics (FATE) as of Q2 2025, up from 132 in Q1 2025.
- Funds reported $88.9M of Fate Therapeutics stock for Q2 2025, up 17% quarter-over-quarter.
- 28 funds opened new Fate Therapeutics positions in Q2 2025 and 21 closed out, a net change of +7 holders.
- The largest Fate Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $656K added.
- The largest Fate Therapeutics seller in Q2 2025 was Schonfeld Strategic Advisors, an estimated $7.98M sold.
Based on aggregated 13F filings for Q2 2025.